Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1691128 | 0.91 | SMN1; SMN2 (0.42) | ALDH1A1POLBLMNAHSD17B10OPRM1 | |
| SCHEMBL1691141 | 0.91 | CYP4F2 (0.41) | ALDH1A1POLBLMNAHSD17B10OPRM1 | |
| SCHEMBL12140578 | 0.90 | SMN1; SMN2 (0.36) | ALDH1A1POLBLMNAHSD17B10OPRM1 | |
| SCHEMBL2185965 | 0.90 | CYP4F2 (0.40) | ALDH1A1POLBOPRM1SMN1; SMN2GAA | |
| SCHEMBL13268736 | 0.86 | OPRM1 (0.50) | ALDH1A1POLBLMNAHSD17B10OPRM1 | |
| SCHEMBL6782433 | 0.86 | TSHR (0.42) | ALDH1A1POLBLMNAOPRM1SMN1; SMN2 | |
| SCHEMBL11920271 | 0.86 | ALDH1A1 (0.40) | ALDH1A1POLBLMNAHSD17B10OPRM1 | |
| SCHEMBL15166991 | 0.85 | POLB (0.40) | ALDH1A1POLBLMNAOPRM1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL20137680 | 0.85 | OPRM1 (0.49) | ALDH1A1POLBOPRM1SMN1; SMN2ALOX15 | |
| SCHEMBL20148097 | 0.85 | OPRM1 (0.51) | POLBLMNAOPRM1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146032-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2026-05-28 | — | — | US | disclosed |
| EP-4748839-A1 | POLYCYCLIC COMPOUND AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026103873-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 杭州百新生物医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12545662-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4660194-A1 | SALT AND CRYSTAL FORM OF CYCLOALKENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2025-12-10 | — | — | EP | disclosed |
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| WO-2025226892-A1 | SPIROCYCLE-CONTAINING DIAMINOMETHYLENE PYRIMIDINE-2,4,6-TRIONE AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4347575-B1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2025-07-23 | — | — | EP | disclosed |
| US-12365658-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2025-07-22 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| CN-1656079-A | Pyrazole compounds and pharmaceutical compositions containing the same | EISAI CO LTD (JP) | 2005-08-17 | — | — | CN | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1368343-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002055518-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-18 | — | — | WO | disclosed |
| US-5416231-A | Prostaglandin I2 derivatives | ASAHI GLASS COMPANY, LTD. (JP) | 1995-05-16 | — | — | US | disclosed |
| EP-0553352-B1 | NOVEL PROSTAGLANDIN I2 DERIVATIVES | ASAHI GLASS CO LTD (JP) | 1995-03-15 | — | — | EP | disclosed |
| EP-0553352-A1 | NOVEL PROSTAGLANDIN I2 DERIVATIVES | ASAHI GLASS COMPANY LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| WO-1992004339-A1 | NOVEL PROSTAGLANDIN I2 DERIVATIVES | ASAHI GLASS COMPANY LTD. (JP) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | ALDH1A1 1714/4885POLB 585/4885LMNA 2847/4885 |
| US-12365658-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | ALDH1A1 688/4885POLB 4853/4885LMNA 3539/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 908/4885POLB 1305/4885LMNA 3592/4885 |
| US-12545662-B2 | MK2 inhibitors and uses thereof | NR3C2, NR2C2, AGTR2 | ALDH1A1 3116/4885POLB 2544/4885LMNA 4609/4885 |
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | BDKRB1, BDKRB2, TACR1 | ALDH1A1 1825/4885POLB 4804/4885LMNA 4111/4885 |
| US-20260146032-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A2, SLC10A1, SLC5A2 | ALDH1A1 1583/4885POLB 4852/4885LMNA 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.